Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18934153 | FILAMENTOUS FUNGUS AND USE THEREOF IN GAS METABOLISM | October 2024 | April 2025 | Allow | 5 | 1 | 0 | No | No |
| 18628247 | Distributed Systems for the Efficient Production and Use of Microbe-Based Compositions | April 2024 | March 2025 | Allow | 11 | 1 | 1 | No | No |
| 18591288 | METHOD AND COMPOSITIONS FOR INHIBITING OR PREVENTING ADVERSE EFFECTS OF ORAL ANTIBIOTICS | February 2024 | April 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18440808 | METHODS FOR ENHANCING IMMUNE CHECKPOINT BLOCKADE THERAPY BY MODULATING THE MICROBIOME | February 2024 | January 2025 | Allow | 11 | 2 | 1 | Yes | No |
| 18432324 | ANTIMICROBIAL HEVAMINE A-RELATED COMPOSITIONS AND METHODS | February 2024 | December 2024 | Allow | 10 | 1 | 1 | Yes | No |
| 18417268 | Anaerobic Blood Storage and Pathogen Inactivation Method | January 2024 | March 2025 | Allow | 14 | 1 | 0 | No | No |
| 18411888 | MULTIUSE, ENZYMATIC DETERGENT AND METHODS OF STABILIZING A USE SOLUTION | January 2024 | November 2024 | Allow | 10 | 1 | 0 | Yes | No |
| 18534962 | MICROBIOME PROTECTION FROM ORAL ANTIBIOTICS | December 2023 | December 2024 | Allow | 12 | 1 | 0 | No | No |
| 18485872 | COMPOSITIONS AND METHODS FOR C. DIFFICILE TREATMENT | October 2023 | August 2024 | Allow | 10 | 1 | 0 | No | No |
| 18478368 | COLLAGENASE FORMULATIONS AND METHODS OF PRODUCING THE SAME | September 2023 | January 2025 | Allow | 16 | 2 | 0 | No | No |
| 18447387 | DISTRIBUTED SYSTEMS FOR THE EFFICIENT PRODUCTION AND USE OF MICROBE-BASED COMPOSITIONS | August 2023 | December 2023 | Allow | 4 | 1 | 0 | No | No |
| 18226559 | PROTEINASE-FREE COATINGS FOR COLONY PASSAGING | July 2023 | August 2024 | Allow | 13 | 1 | 0 | No | No |
| 18217743 | COMPOSITIONS AND METHODS FOR TREATMENT OF SKIN-RELATED DISEASES AND PROMOTING DERMATOLOGICAL HEALTH | July 2023 | June 2025 | Allow | 23 | 2 | 0 | No | No |
| 18210901 | MICROORGANISMS AND ARTIFICIAL ECOSYSTEMS FOR THE PRODUCTION OF PROTEIN, FOOD, AND USEFUL CO-PRODUCTS FROM C1 SUBSTRATES | June 2023 | April 2025 | Allow | 22 | 2 | 0 | Yes | No |
| 18328874 | LIQUID SPORULATION METHOD AND SPORULATION BROTH | June 2023 | October 2024 | Allow | 17 | 3 | 0 | Yes | No |
| 18326267 | DEVELOPMENT OF AMYLOGLUCOSIDASE AS A MEDICINAL FOOD OR DIETARY SUPPLEMENT | May 2023 | September 2024 | Allow | 15 | 1 | 0 | Yes | No |
| 18200557 | Methods and Compositions for the Treatment of Steatosis-Associated Disorders | May 2023 | August 2024 | Allow | 15 | 1 | 0 | No | No |
| 18193086 | USE OF PLATELET RICH PLASMA COMPOSITION IN THE TREATMENT OF CARDIAC CONDUCTION ABNORMALITIES | March 2023 | September 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18126459 | SYSTEMS AND METHODS FOR GROWING A BIOFILM OF PROBIOTIC BACTERIA ON SOLID PARTICLES FOR COLONIZATION OF BACTERIA IN THE GUT | March 2023 | April 2025 | Allow | 25 | 2 | 0 | No | No |
| 18172021 | ENHANCED CAFFEINATED BEVERAGE COMPOSITION | February 2023 | October 2023 | Allow | 8 | 1 | 0 | No | No |
| 18163648 | METHOD AND COMPOSITIONS FOR INHIBITING OR PREVENTING ADVERSE EFFECTS OF ORAL ANTIBIOTICS | February 2023 | February 2024 | Allow | 13 | 1 | 0 | No | No |
| 18159934 | METHODS OF SYNERGISTIC TREATMENT OF CANCER | January 2023 | May 2024 | Allow | 16 | 1 | 0 | Yes | No |
| 18096853 | ADENO-ASSOCIATED VIRUS FORMULATIONS | January 2023 | July 2024 | Allow | 19 | 2 | 1 | Yes | No |
| 17997959 | LONG-LIVING, THERMOTOLERANT YEAST AND USE THEREOF IN PRODUCING A FERMENTED BEVERAGE | November 2022 | November 2024 | Allow | 24 | 1 | 1 | Yes | No |
| 18049791 | MICROBIOME PROTECTION FROM ORAL ANTIBIOTICS | October 2022 | September 2023 | Allow | 11 | 1 | 0 | No | No |
| 17891810 | COMPOSITION AND METHODS FOR REDUCING CORN-ON-CORN YIELD PENALTY | August 2022 | December 2023 | Allow | 16 | 1 | 0 | No | No |
| 17818668 | Anaplerotic Oil Production In Microbials | August 2022 | February 2024 | Abandon | 18 | 1 | 1 | No | No |
| 17884346 | THEACRINE-BASED SUPPLEMENT AND METHOD OF USE THEREOF IN A SYNERGISTIC COMBINATION WITH CAFFEINE | August 2022 | May 2023 | Allow | 9 | 1 | 0 | No | No |
| 17873504 | METHODS OF GENERATING, REPAIRING AND/OR MAINTAINING CONNECTIVE TISSUE IN VIVO | July 2022 | October 2024 | Allow | 26 | 3 | 1 | No | No |
| 17814739 | MICROBIAL FERMENTATION METHODS AND COMPOSITIONS | July 2022 | February 2024 | Allow | 18 | 1 | 1 | Yes | No |
| 17814314 | METHODS FOR ENHANCING IMMUNE CHECKPOINT BLOCKADE THERAPY BY MODULATING THE MICROBIOME | July 2022 | January 2025 | Allow | 30 | 1 | 2 | Yes | No |
| 17793942 | Use of a defoamer for maintaining dispersed morphology in submerged fungal fermentation | July 2022 | August 2024 | Allow | 25 | 2 | 1 | Yes | No |
| 17862028 | ACCELERATED DIRECTED EVOLUTION OF MICROBIAL CONSORTIA FOR THE DEVELOPMENT OF DESIRABLE PLANT PHENOTYPIC TRAITS | July 2022 | July 2023 | Allow | 12 | 1 | 0 | No | No |
| 17806303 | SYNERGISTIC CELLULASE-SURFACTANT INTERACTIONS FOR DEGRADATION OF BACTERIAL CELLULOSE | June 2022 | August 2023 | Allow | 14 | 1 | 0 | Yes | No |
| 17784055 | METHOD FOR PREPARING CULTURES OF LACTIC ACID BACTERIA | June 2022 | January 2024 | Allow | 19 | 1 | 1 | Yes | No |
| 17805753 | ANTIMICROBIAL HEVAMINE A-RELATED COMPOSITIONS AND METHODS | June 2022 | January 2024 | Allow | 19 | 1 | 1 | Yes | No |
| 17776529 | Fermentation fungal substance of Astragalus membranaceus/Paecilomyces cicadae and its use | May 2022 | September 2023 | Allow | 16 | 1 | 1 | Yes | No |
| 17717678 | ROSEBURIA HOMINIS HGM001 ISOLATE AND USE THEREOF | April 2022 | June 2024 | Allow | 26 | 2 | 0 | No | No |
| 17716939 | BACTERIOPHAGES FOR TREATMENT OF TUBERCULOSIS | April 2022 | February 2024 | Allow | 22 | 1 | 1 | Yes | No |
| 17767181 | COMPOSITION FOR IMPROVING RESPIRATORY DISEASES USING LACTOBACILLUS PLANTARUM STRAIN | April 2022 | April 2025 | Allow | 36 | 1 | 0 | No | No |
| 17766959 | YEAST FOR THE TREATMENT OF ALLERGY | April 2022 | November 2024 | Allow | 31 | 2 | 0 | Yes | No |
| 17761490 | USE OF MICROORGANISM TO IMPROVE PLANT PRODUCTIVITY OF SOIL | March 2022 | February 2024 | Allow | 23 | 2 | 1 | No | No |
| 17696959 | Bifidobacterium Breve capable of relieving rheumatoid arthritis and application thereof | March 2022 | March 2025 | Allow | 36 | 1 | 1 | No | No |
| 17690879 | COMPOSITIONS AND METHODS FOR PROMOTING A HEALTHY MICROBIAL FLORA IN A MAMMAL | March 2022 | October 2024 | Allow | 31 | 3 | 1 | Yes | No |
| 17686466 | DIGITAL MICROBIOLOGY | March 2022 | December 2023 | Allow | 21 | 1 | 1 | No | No |
| 17639161 | BACTERIAL OIL TREATMENT COMPOSITION FOR HANDLING A DECOMMISSIONED OIL CABLE | February 2022 | March 2024 | Allow | 24 | 1 | 1 | Yes | No |
| 17635991 | PRODUCTION OF MONOACYL MEL | February 2022 | January 2025 | Allow | 35 | 1 | 0 | Yes | No |
| 17630450 | METHODS AND COMPOSITIONS FOR CONTROLLING OR REDUCING PESTS | January 2022 | February 2025 | Allow | 36 | 2 | 1 | Yes | No |
| 17629149 | FAECALIBACTERIUM PRAUSNITZII AND CHRISTENSENELLA BACTERIAL STRAINS FOR THE TREATMENT AND PREVENTION OF BOWEL INFLAMMATION | January 2022 | August 2024 | Abandon | 31 | 0 | 1 | No | No |
| 17576733 | COMPOSITIONS AND METHODS OF IMPROVING RUMINANT PERFORMANCE | January 2022 | August 2024 | Allow | 31 | 2 | 1 | Yes | No |
| 17279386 | METHODS AND COMPOSITIONS TO TREAT AND PREVENT INFECTION | January 2022 | May 2025 | Allow | 50 | 1 | 1 | No | No |
| 17623936 | Bifidobacterium breve CCFM1025, Food Fermented Thereby and Application Thereof | December 2021 | June 2025 | Abandon | 41 | 1 | 1 | No | No |
| 17559006 | Application of Dubosiella Newyorkensis in Prolonging Lifespan and Anti-Aging | December 2021 | December 2024 | Abandon | 36 | 1 | 0 | No | No |
| 17618681 | Bacillus Thuringiensis Strain | December 2021 | November 2024 | Abandon | 35 | 0 | 1 | No | No |
| 17545777 | MEDICINAL VAGINAL LACTOBACILLUS COCKTAIL | December 2021 | March 2025 | Allow | 40 | 2 | 1 | Yes | No |
| 17543407 | TREATMENT FOR AIRWAY CAST OBSTRUCTION | December 2021 | May 2024 | Allow | 29 | 2 | 0 | Yes | No |
| 17537714 | Production of 2-Hydroxyacyl-CoAs and Derivatives Thereof | November 2021 | March 2025 | Allow | 40 | 1 | 1 | No | No |
| 17614982 | GABA-PRODUCING CULTURABLE BACTERIA AND USE FOR IMPROVING HEALTH | November 2021 | June 2025 | Allow | 43 | 2 | 1 | Yes | No |
| 17455578 | COMPOSITIONS AND METHODS COMPRISING BACTERIA FOR IMPROVING BEHAVIOR IN NEURODEVELOPMENTAL DISORDERS | November 2021 | February 2023 | Allow | 15 | 1 | 0 | Yes | No |
| 17525759 | SUBCUTANEOUS ADMINISTRATION OF ADAMTS13 | November 2021 | May 2023 | Allow | 18 | 1 | 0 | No | No |
| 17524923 | AIRWAY MEDICAMENTS | November 2021 | March 2023 | Allow | 16 | 4 | 1 | Yes | No |
| 17518810 | CONIOTHYRIUM MINITANS FOR PROTECTION OF CULTIVATED PLANTS FROM ATTACKS BY FUNGAL PATHOGENS BELONGING TO THE GENUS PHOMA SPP. OR VERTICILLIUM SPP. | November 2021 | September 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17517410 | Microbial Lysozyme for use in the Treatment of Irritable Bowel Syndrome or Inflammatory Bowel Disease | November 2021 | March 2024 | Allow | 28 | 1 | 1 | Yes | No |
| 17494733 | METHOD FOR IMPROVING INTESTINAL FLORA | October 2021 | July 2023 | Allow | 22 | 1 | 0 | No | No |
| 17598878 | PROBIOTIC BIOFILM COMPOSITIONS AND METHODS OF PREPARING SAME | September 2021 | February 2025 | Abandon | 41 | 3 | 1 | No | No |
| 17482846 | Anaerobic Blood Storage and Pathogen Inactivation Method | September 2021 | October 2023 | Allow | 25 | 1 | 1 | Yes | No |
| 17447835 | AGENT FOR USE IN THE CASE OF FRUCTOSE INTOLERANCE | September 2021 | July 2023 | Allow | 22 | 1 | 0 | No | No |
| 17437492 | BACTERIUM OF THE CHRISTENSENELLACEAE FAMILY FOR THE PREVENTION AND/OR TREATMENT OF CHRONIC INFLAMMATORY DISEASES AND/OR INFLAMMATORY GASTROINTESTINAL DISEASES AND/OR CANCERS | September 2021 | August 2024 | Abandon | 35 | 1 | 2 | No | No |
| 17436693 | BACTERIOPHAGE FOR MODULATING INFLAMMATORY BOWEL DISEASE | September 2021 | April 2025 | Allow | 43 | 1 | 1 | No | No |
| 17462227 | SELECTION OF BACTERIAL STRAINS USEFUL IN ALLERGY TREATMENT | August 2021 | October 2024 | Allow | 37 | 2 | 0 | No | No |
| 17461481 | METHOD OF ASSESSING AND TREATING CELLULITE | August 2021 | August 2023 | Allow | 23 | 1 | 1 | Yes | No |
| 17433427 | COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING OBESITY OR FATTY LIVER DISEASE, COMPRISING LEUCONOSTOC CITREUM WIKIM0104 | August 2021 | July 2024 | Allow | 35 | 1 | 0 | No | No |
| 17408397 | Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders | August 2021 | March 2024 | Allow | 30 | 2 | 1 | Yes | No |
| 17394609 | METHOD AND PRODUCT FOR PREPARING A PROTEIN-CONTAINING SAMPLE FOR ANALYSIS BY MASS SPECTROMETRY | August 2021 | October 2023 | Allow | 26 | 1 | 1 | No | No |
| 17384003 | METHODS AND SYSTEMS FOR STARCH BASED PROPAGATION OF A MICROORGANISM | July 2021 | January 2024 | Allow | 30 | 2 | 1 | Yes | No |
| 17421154 | PRODUCT FOR THE TREATMENT OF DYSBIOSIS | July 2021 | July 2025 | Allow | 48 | 2 | 1 | No | No |
| 17419899 | COLLAGENASE FORMULATIONS AND METHODS OF PRODUCING THE SAME | June 2021 | February 2024 | Abandon | 31 | 0 | 1 | No | No |
| 17350159 | CRYSTALLIZED OXALATE DECARBOXYLASE AND METHODS OF USE | June 2021 | July 2023 | Abandon | 25 | 0 | 1 | No | No |
| 17339909 | USE OF IN-SITU IONIC LIQUID (IL) AND DEEP EUTECTIC SOLVENT (DES) SYNTHESIS USING CHEMICALLY SYNTHESIZED OR BIOMASS-DERIVED IONS IN THE PRETREATMENT OF BIOMASS | June 2021 | April 2025 | Allow | 47 | 4 | 0 | Yes | No |
| 17299392 | CHOLINE ACETYLTRANSFERASE AS A THERAPY FOR HYPERTENSION | June 2021 | July 2024 | Allow | 38 | 2 | 1 | No | No |
| 17295324 | EXOSOME AND VARIOUS USES THEREOF | May 2021 | December 2023 | Abandon | 31 | 0 | 1 | No | No |
| 17316728 | PIGLET FEED BASED ON BACTERIAL ENZYME SYNERGISTIC FERMENTATION PROCESS AND PREPARATION METHOD THEREOF | May 2021 | September 2023 | Allow | 28 | 1 | 0 | Yes | No |
| 17292495 | STRAINS OF PENICILLIUM CAMEMBERTI | May 2021 | January 2023 | Allow | 20 | 1 | 1 | Yes | No |
| 17246119 | METHODS AND COMPOSITIONS FOR CNS DELIVERY OF ARYLSULFATASE A | April 2021 | September 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17242256 | USE OF ENSILED BIOMASS FOR INCREASED EFFICIENCY OF THE PRETREATMENT OF BIOMASS | April 2021 | August 2023 | Abandon | 28 | 2 | 1 | Yes | No |
| 17282341 | COMPOSITIONS AND METHODS FOR ENZYMATIC DISRUPTION OF BACTERIAL BIOFILMS | April 2021 | July 2024 | Allow | 40 | 2 | 1 | Yes | No |
| 17301253 | MULTIUSE, ENZYMATIC DETERGENT AND METHODS OF STABILIZING A USE SOLUTION | March 2021 | October 2023 | Allow | 30 | 1 | 1 | Yes | No |
| 17281240 | USE OF GLUTAMINE SYNTHETASE FOR TREATING FATTY LIVER DISEASE | March 2021 | May 2025 | Allow | 50 | 2 | 1 | Yes | No |
| 17215270 | ALKALINE PHOSPHATASE FORMULATIONS | March 2021 | March 2024 | Allow | 36 | 1 | 0 | No | No |
| 17278438 | PESTICIDAL COMBINATIONS OF YERSINIA AND INSECT VIRUSES | March 2021 | November 2024 | Abandon | 44 | 1 | 1 | No | No |
| 17208696 | REDUCING INSOLUBLE DEPOSIT FORMATION IN ETHANOL PRODUCTION | March 2021 | June 2023 | Allow | 27 | 1 | 1 | Yes | No |
| 17276754 | METHOD FOR INCREASING STORAGE STABILITY OF FUNGAL SPORES | March 2021 | November 2024 | Abandon | 44 | 1 | 1 | No | No |
| 17201526 | DELIVERING ENZYME USING AN INJECTABLE HYDROGEL DEPOT | March 2021 | March 2025 | Abandon | 48 | 2 | 1 | No | No |
| 17275801 | ANIMAL FEED COMPOSITION AND USE THEREOF | March 2021 | September 2024 | Abandon | 42 | 1 | 1 | No | No |
| 17274610 | COMPOSITION FOR INHIBITING TRYPSIN ACTIVITY CONTAINING AS ACTIVE INGREDIENT BACTERIUM BELONGING TO GENUS PARAPREVOTELLA | March 2021 | May 2023 | Abandon | 27 | 1 | 1 | No | No |
| 17190018 | Methods and Compositions for the Treatment of Steatosis-Associated Disorders | March 2021 | February 2023 | Allow | 24 | 1 | 0 | Yes | No |
| 17271940 | MUTANT STRAIN OF TRICHODERMA REESEI AND METHOD OF PRODUCING PROTEIN USING SAME | February 2021 | March 2025 | Allow | 48 | 4 | 1 | No | No |
| 17270674 | EXTRACELLULAR VESICLES AS BIOMARKERS AND THERAPEUTICS FOR NEUROMUSCULAR DISORDERS | February 2021 | April 2025 | Allow | 49 | 3 | 1 | Yes | No |
| 17269951 | SUCROSE ISOMERASES AS FOOD AND NUTRITIONAL SUPPLEMENTS | February 2021 | June 2025 | Abandon | 52 | 3 | 1 | No | No |
| 17269234 | COMPOSITIONS FOR USE TO TREAT ADVANCED GLYCATION END PRODUCTS-DEPENDENT OCULAR DISEASES | February 2021 | August 2024 | Allow | 42 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ARIANI, KADE.
With a 61.5% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 34.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner ARIANI, KADE works in Art Unit 1651 and has examined 925 patent applications in our dataset. With an allowance rate of 66.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.
Examiner ARIANI, KADE's allowance rate of 66.4% places them in the 20% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ARIANI, KADE receive 2.02 office actions before reaching final disposition. This places the examiner in the 66% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by ARIANI, KADE is 32 months. This places the examiner in the 30% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +46.8% benefit to allowance rate for applications examined by ARIANI, KADE. This interview benefit is in the 93% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 31.4% of applications are subsequently allowed. This success rate is in the 56% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 32.3% of cases where such amendments are filed. This entry rate is in the 39% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 93.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 67% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 81.7% of appeals filed. This is in the 71% percentile among all examiners. Of these withdrawals, 53.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 68.3% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 2.7% of allowed cases (in the 81% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.3% of allowed cases (in the 46% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.